A Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure.

ClinicalTrials.gov ID: NCT07222917

Public ClinicalTrials.gov record NCT07222917. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 20, 2026, 10:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase IIb, Randomised, Multicentre, Double-Blind Study to Evaluate the Effect of Baxdrostat in Combination With Dapagliflozin Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure.

Study identification

NCT ID: NCT07222917
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 2
Lead sponsor: AstraZeneca; Industry
Enrollment: 218 participants

Conditions and interventions

Conditions

Chronic Kidney Disease and Hypertension

Interventions

Baxdrostat/Placebo Drug
Baxdrostat/dapagliflozin Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Dec 4, 2025
Primary completion: May 23, 2027
Completion: May 23, 2027
Last update posted: May 17, 2026

2025 – 2027

United States locations

U.S. sites: 18
U.S. states: 12
U.S. cities: 18

Facility	City	State	ZIP	Site status
Research Site	Surprise	Arizona	85374	Recruiting
Research Site	Hollywood	Florida	33021	Recruiting
Research Site	Port Charlotte	Florida	33952	Recruiting
Research Site	Port Orange	Florida	32127	Recruiting
Research Site	Atlanta	Georgia	30344	Recruiting
Research Site	Champaign	Illinois	61822	Recruiting
Research Site	Wichita	Kansas	67214	Recruiting
Research Site	Eatontown	New Jersey	07724	Recruiting
Research Site	Greenville	North Carolina	27834	Recruiting
Research Site	Jacksonville	North Carolina	28546	Recruiting
Research Site	New Bern	North Carolina	28562	Recruiting
Research Site	Columbus	Ohio	43215	Recruiting
Research Site	Media	Pennsylvania	19063	Recruiting
Research Site	East Providence	Rhode Island	02914	Recruiting
Research Site	Arlington	Texas	76015	Recruiting
Research Site	Pasadena	Texas	77504	Recruiting
Research Site	San Antonio	Texas	78212	Recruiting
Research Site	Woodbridge	Virginia	22192	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 52 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07222917, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted May 17, 2026 · Synced May 20, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07222917 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →